Travere Therapeutics
Open
$53.51
Prev. Close
$53.70
High
$53.51
Low
$53.33
Market Snapshot
$4.92B
-229.9
-4.08
$233.18M
497
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 497 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Director Roy Baynes sold 4,500 shares of Travere Therapeutics, decreasing his ownership to 41,500 shares amid ongoing developments in the biotech industry.
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 497 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Recently from Cashu
Travere Therapeutics Reports Positive FILSPARI Results and Achieves First Profitable Quarter
Travere Therapeutics (Ticker: TVTX) shows promising advancements in its drug FILSPARI, vital in treating focal segmental glomerulosclerosis (FSGS). Recently, the company released positive long-term da…
Travere Therapeutics Secures Patent, Strengthens Position in Rare Kidney Disease Market
Travere Therapeutics (Ticker: TVTX) strengthens its position in the rare kidney disease market with recent patent developments. Patent Protection for FILSPARI Enhances Market Position The company focu…
Travere Therapeutics Secures Patent for FILSPARI, Strengthening IgA Nephropathy Treatment Efforts
Travere Therapeutics (Ticker: TVTX) has recently made headlines with a significant milestone for its drug FILSPARI, specifically developed for the treatment of IgA nephropathy. The U.S. Patent and Tra…
Travere Therapeutics Achieves FDA Approval for FILSPARI®: A Breakthrough in FSGS Treatment
Travere Therapeutics celebrates a significant milestone with FDA approval of its medication FILSPARI® (sparsentan), marking it as the first and only treatment designed for patients with Focal Segmenta…